Discover investment opportunities in Pharm Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Pharm Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Pharm Stocks using our Smart AI Filter.
10 stocks found for "Pharm Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.45 | ±25.0% | 14.4 | 3.19% | |||
0.45 | ±20.5% | 12.7 | 3.02% | |||
0.33 | ±27.9% | 8.6 | 4.00% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.32 | ±24.8% | 8.7 | 6.75% | |||
0.22 | ±27.3% | 15.0 | 2.83% | |||
0.37 | ±19.7% | 14.7 | 3.18% | |||
0.59 | ±31.6% | 34.5 | 0.77% | |||
0.35 | ±28.9% | 6.7 | 5.29% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How does the drug pipeline influence the stock prices of companies like PFE and MRK?
A: Drug pipelines are critical as they represent future revenue streams. Successful trials and FDA approvals can boost stock prices for companies like PFE and MRK, while clinical setbacks can lead to declines. Investors monitor these pipelines closely to assess growth potential.
Q: Why might a company like ABBV be attractive for dividend-seeking investors?
A: ABBV is known for its high dividend yield, supported by strong cash flow from key products. Dividend-seeking investors may find ABBV attractive due to its commitment to returning capital to shareholders, but it's essential to consider financial health and sustainability.
Q: What risks are associated with investing in biotech companies such as REGN and VRTX?
A: Biotech investments like REGN and VRTX carry risks including clinical trial failures, high R&D expenses, and regulatory uncertainty. Additionally, pricing pressures and competitive landscapes can impact potential profitability.
Q: How do changes in healthcare policies affect companies like BMY and JNJ?
A: Healthcare policy changes can significantly impact BMY and JNJ, influencing drug pricing, market access, and operational costs. Policy shifts towards price controls can pressure revenues, while favorable regulations may drive growth.
Q: What role do patent expirations play for pharmaceuticals companies such as LLY and AMGN?
A: Patent expirations can lead to revenue declines for companies like LLY and AMGN due to generics entering the market. Investors must evaluate how companies plan to mitigate this through new drug launches or diversification.
Q: Why are research and development (R&D) expenditures critical for GILD and similar pharmaceutical companies?
A: R&D is crucial for companies like GILD as it fuels innovation for future growth. High R&D spending indicates focus on developing cutting-edge therapies but represents a financial commitment that impacts profitability.
Amgen said it will spend more than $600 million to build a new research and development facility at its headquarters in Thousand Oaks, California. It is the latest in a string of new U.S. investments by the pharmaceutical industry as President Donald Trump threatens to clamp down on the industry with tariffs on pharmaceuticals imported into the country.
Read morePresident Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read morePresident Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
Read more